You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

CMEC Meeting 06, 10 June 1998

Complementary Medicines Evaluation Committee

10 June 1998

Extracted ratified minutes

How to access a pdf document

CMEC Meeting 6 extracted ratified minutes (pdf,48kb)

Public recommendation summary

Item 3.1.4 Safety of ginger - item 3.3.1 of CMEC5 referred

Recommendation to TGA:

  1. Further studies are required on the effect of concentrated ginger products such as Zinax on platelet action in humans;
  2. Until such time that the studies are carried out, Zinax products are to contain the following warning statements:
    • 'Individuals taking anticoagulants should seek medical advice before taking this product'
    • 'Individuals at risk of bleeding problems, should seek advice from their health practitioner prior to taking this product'
  3. The company be advised that CMEC is considering the information contained in the insert with a view to requesting the company to modify it in the light of recommendations 1 & 2 above especially in relation to the statement 'The patented extraction process also ensures that the mucous membranes in the stomach and colon are not irritated'.

Item 4 Evaluation of new substances

Item 4.1 Probiotic organism

Recommendation to TGA:

  • that existing strains of Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum, subject to information on what strains are currently in use in therapeutic goods, should be suitable for use in listable therapeutic goods.

Recommendation to TGA:

  • that other probiotics could be suitable for use in listed products.

Top of page